Appreciate this article brings all the information together but in a calm and professional manner if you read it carefully it still is based on opinion, words like we believe or Likely or in our opinion, being used. Unless you were one of those who prescribed to the belief that Teva had any info re the trials that led them to the decision to walk( which I for one was not) this report did not really provide me with any really new information. I am a LT holder and have no plans to change my holdings at this stage but the most significant thing that this report could not provide us with and Mangement need to within the predicted 2 weeks is just how they will now fund the CHF trial and provide us with some hope that they really do have partnership discussions progressing. Without more details on this unfortunately the risk of this investments will continue to rise and the SP will continue to fall.
Of course I hope this is not the case, as I am not in the habit of loosing money and would not like to see such a great therapy no advance as it should for the sake of all those people in need of such a breakthrough.
Have a great week end.
MSB Price at posting:
$1.06 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)